- Mumbai-based Cipla said it has over 200 drugs in its pipeline and expects the top 50 of those drugs to have a $30 billion potential. Its pipeline products range from respiratory therapeutics to HIV and oncology therapies
- Cipla plans to grow its North American business to a 25% share of its business by 2020, from the current share of 8% of total sales.
- The growth will come on the back of an increased focus on gaining U.S. approval for generic drugs.
Cipla hopes to strengthen its organic presence in the North American market, planning 10-15 abbreviated new drug applications(ANDAs) per year. It recently acquired two U.S. companies, InvaGen Pharmaceutical and Exelan Pharmaceutical, in deal which was expected to close last month.
In an investor call in September of last year, Cipla said the agreement with the two companies would give it 40 approved ANDAs and 30 pipeline products.